Zhifei Biological Expands Vaccine Partnership with Merck

Did you know?

ChinaBio^® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…

More white papers:

>>China Partnering 2012: Driving Future Innovation

>>China Life Science 2012: From Local to Global

Free Content

Week in Review

In My Opinion

Free Articles

Education Center

Interfax-BW Releases

Subscriber Content

Zhifei Biological Expands Vaccine Partnership with Merck

publication date: Jun 8, 2012

Chongqing Zhifei Biological Products and Merck signed an MOU that expands the existing partnership between the two companies by entrusting Zhifei with the responsibility for China marketing of Merck’s RotaTeq, an oral pentavalent live rotavirus vaccine. Merck, known as MSD outside the US and Canada, already sells the vaccine in 85 countries. Last year, Zhifei took over the China marketing of Merck’s MMR/rubella and Penumovax 23 vaccines. More details....

Stock Symbols: (SHE: 300122) (NYSE: MRK)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Click here to join.